LaZure Scientific, Inc. is a development stage medical device company pioneering LDAC Technology, a proprietary, breakthrough cancer treatment method that employs low dose, alternating electric current to preferentially destroy cancer cells. LaZure’s first treatment device using LDAC is designed to provide effective, whole-gland treatment of early stage prostate cancer without creating serious side effects such as impotence and incontinence. The LDAC Technology is currently being used in human clinical trials at multiple international locations. A total of 46 patients have been treated in the on-going human trials. This device is currently for investigational use only and has not been cleared for use in the U.S. by the FDA.
Pre-clinical testing has shown that the technology is effective in a number of other cancer indications. Although prostate cancer was selected as the first cancer indication for clinical testing, the technology is well suited for use in other cancer indications.